Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2012

View Archived Issues

Novartis identifies new class of compounds for treating cystic fibrosis

Daiichi Sankyo profiles highlights of fiscal 2011

Roche reports novel agents for raising HDL cholesterol

First results for phase II COMPLETE study of eculizumab presented

Genetic basis of TAR syndrome uncovered

Dainippon Sumitomo Pharma updates activities of fiscal 2011

Spanish researchers patent new agents for Gaucher's disease

Novel monoglyceride lipase inhibitors presented by Janssen Pharmaceutica

Elevation Pharmaceuticals reports phase IIb results for EP-101 in COPD

InterMune patents new agents for hepatitis and liver disorders

Cytomedix expands phase II RECOVER-Stroke study

Astellas Pharma and CoMentis present novel compounds for Alzheimer's disease

Biosceptre collaborates with Australian facilities on cancer antibody research

Achaogen provides update on plazomicin and ACHN-975 programs

New inhibitors of serotonin receptor binding synthesized at Epiomed Therapeutics

Abbott presents clinical results for their antiviral candidate ABT-072

Major Alzheimer's disease prevention study commences

Fibrocell Science enters two new agreements

Pfizer reports topline results from phase III Torisel study

Antibodies targeting misfolded Fas receptor protein disclosed

BG Medicine obtains expanded indication for Galectin-3 test in E.U., files for clearance in U.S.

Repros submits documents to FDA for Androxal SPA

Amgen provides updated blinatumomab results

Neuren Pharmaceuticals and FDA hold pre-IND meeting for NNZ-2566

Ark Therapeutics gives update on VEGF-D adenoviral vector treatment study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...